Lipolytic methods

Abstract

Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.

1 - 31 . (canceled) 
     
     
         32 . A method of inducing lipolysis or reducing fat accumulation, adipose tissue, cellulite, or regional fat deposit, comprising administering an injectable formulation to a subject comprising an effective amount of a lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof in an amount that is up to about 250 micrograms per week, wherein the administration is less frequently than every day. 
     
     
         33 . The method of  claim 32 , wherein the lipophilic long-acting selective beta-2 agonist comprises salmeterol, formoterol, bambuterol, or a salt, solvate, or combinations thereof. 
     
     
         34 . The method of  claim 33 , wherein the lipophilic long-acting selective beta-2 agonist comprises salmeterol, or a salt, solvate, or combinations thereof. 
     
     
         35 . The method of  claim 34 , wherein the lipophilic long-acting selective beta-2 agonist comprises salmeterol xinafoate. 
     
     
         36 . The method of  claim 33 , wherein the lipophilic long-acting selective beta-2 agonist comprises formoterol, or a salt, solvate, or combinations thereof. 
     
     
         37 . The method of  claim 36 , wherein the lipophilic long-acting selective beta-2 agonist comprises formoterol fumarate. 
     
     
         38 . The method of  claim 32 , wherein the formulation comprises a liquid carrier or a pharmaceutically acceptable excipient that is formulated for injection into a layer of subcutaneous fat in the subject. 
     
     
         39 . The method of  claim 32 , wherein the injectable formulation is suitable for subcutaneous administration or transdermal administration. 
     
     
         40 . The method of  claim 32 , wherein the lipolysis, the fat accumulation, the adipose tissue, the cellulite, or the regional fat deposit is located in the submental region, the waist region, the hip region, the buttock region, the back region, the arm region, or the thigh region of a human. 
     
     
         41 . The method of  claim 38 , wherein the subcutaneous fat comprises periorbital fat, submental fat, abdominal fat, waist fat, hip fat, or thigh fat. 
     
     
         42 . The method of  claim 32 , wherein the lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof is administered in an amount that is up to about 100 micrograms per week. 
     
     
         43 . The method of  claim 32 , wherein the lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof is administered in an amount that is up to about 50 micrograms per week. 
     
     
         44 . The method of  claim 32 , wherein the lipophilic long-acting selective beta-2 agonist is administered by single needle injection or by needleless injection. 
     
     
         45 . The method of  claim 34 , wherein the effective amount of salmeterol, or a salt, solvate, or combinations thereof is up to about 100 micrograms per day. 
     
     
         46 . The method of  claim 36 , wherein the effective amount of formoterol, or a salt, solvate, or combinations thereof is up to about 50 micrograms per day. 
     
     
         47 . The method of  claim 32 , wherein the method provides an effect that is at least partially cosmetic. 
     
     
         48 . The method of  claim 32 , wherein the method provides an effect that is at least partially therapeutic. 
     
     
         49 . A method comprising contacting adipose tissue, cellulite, regional fat deposit, or fat accumulation, less frequently than every day, with an injectable formulation comprising an effective amount of a lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof in an amount that is up to about 250 micrograms per week and that causes lipolysis or reduces fat accumulation, adipose tissue, cellulite, or regional fat deposit in the subject. 
     
     
         50 . A method of treating fat accumulation, adipose tissue, cellulite, or regional fat deposit in a subject, comprising administering by injection, less frequently than every day, an effective amount of a lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof, wherein the effective amount is sufficient to induce tissue concentration of the lipophilic long-acting selective beta-2 agonist to a concentration between about 1 picomolar to about 100 micromolar. 
     
     
         51 . The method of  claim 50 , wherein the tissue concentration of between about 1 picomolar to about 100 micromolar is maintained between the administrations of the lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof.